June 11th 2025
During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy toxicity and how to coordinate with CAR T providers.
Do Race and Ethnicity Affect Response to CAR T-Cell Therapy?
October 27th 2023While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Read More
Cilta-Cel Continues to Elicit Positive Responses in R/R Multiple Myeloma
October 24th 2023In an interview with Targeted Oncology, Yi Lin, MD, PhD, discussed the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Read More
Emerging CAR T-Cell Therapies in Large B-Cell Lymphoma
September 13th 2023In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment of patients with LBCL.
Read More
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than Expected
September 9th 2023Widespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Read More
Assessing Available CAR T-Cell Agents for DLBCL
August 7th 2023Frederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.
Watch
Although Promising, CAR T-Cell Therapy in T-ALL Carries Many Challenges
August 5th 2023Though chimeric antigen receptor T cells are showing promise in T-cell acute lymphoblastic leukemia, challenges, including those related to manufacture, those that are patient/disease specific, and those regarding risk mitigation, remain a struggle.
Read More